D. Ramsden

发表

Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates

D. Tweedie, N. Hariparsad, M. Mohutsky, 2019, Drug Metabolism and Disposition.

General Principles of Drug Distribution

M. Grant, D. Ramsden, Gillian C. Wallace, 2012 .

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective

Hongbing Wang, M. Shebley, Liangfu Chen, 2016, Drug Metabolism and Disposition.

Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model

Andrea Whitcher-Johnstone, E. S. Perloff, D. Ramsden, 2021, Drug Metabolism and Disposition.

Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation

D. Tweedie, Jun Xu, Yongmei Li, 2014, Drug Metabolism and Disposition.

The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study

C. Almansa, D. Ramsden, Susanna Y. Huh, 2022, Clinical and translational science.

The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

M. Manoharan, S. Chong, K. Charissé, 2022, Drug Metabolism and Disposition.

Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

M. Manoharan, S. Chong, K. Charissé, 2022 .

Characterization of Correction Factors to Enable Assessment of Clinical Risk from In Vitro CYP3A4 Induction Data and Basic Drug-Drug Interaction Models

D. Ramsden, Cody L. Fullenwider, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

DMD057901 1940..1946

D. Tweedie, T. Tracy, T. Chan, 2014 .

Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics.

Sara C. Humphreys, S. Stahl, David G. Belair, 2021, ALTEX.

Generating an In Vitro–In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac)

D. Tweedie, Yongmei Li, D. Ramsden, 2014, Drug Metabolism and Disposition.

DMD055947 407..414

D. Tweedie, Yongmei Li, R. George, 2014 .

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

D. Tweedie, R. Walsky, N. Hariparsad, 2017, Drug Metabolism and Disposition.

Hydrogen Bonding of Water in Substances containing the Amide Group

D. Ramsden, G. King, F. Wood, 1966, Nature.

Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac

D. Tweedie, Jin Zhou, D. Ramsden, 2015, Drug Metabolism and Disposition.

Mass Balance, Metabolite Profile, and In Vitro-In Vivo Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor

R. Sane, D. Ramsden, B. Latli, 2014, Antimicrobial Agents and Chemotherapy.

M. Manoharan, S. Chong, K. Charissé, 2021, Drug Metabolism and Disposition.

In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters

S. Chong, Valerie A. Clausen, Yongli Gu, 2019, Drug Metabolism and Disposition.

ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

N. Hariparsad, D. Ramsden, D. Mcginnity, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Altered CYP2C9 Activity Following Modulation of CYP3A4 Levels in Human Hepatocytes: an Example of Protein-Protein Interactions

D. Tweedie, T. Tracy, T. Chan, 2014, Drug Metabolism and Disposition.

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

C. Scarpignato, I. Michon, H. Jones, 2023, CPT: pharmacometrics & systems pharmacology.

Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance

D. Tweedie, R. Walsky, N. Hariparsad, 2018, Drug Metabolism and Disposition.

General principles of drug disposition

M. Grant, D. Ramsden, Gillian C. Wallace, 2012 .

Challenges and Opportunities for Improved Drug–Drug Interaction Predictions for Renal OCT2 and MATE1/2‐K Transporters

N. Hariparsad, Joanne Wang, S. Stahl, 2022, Clinical pharmacology and therapeutics.

97—DIFFUSION OF SOME SULPHONIC ACIDS IN KERATIN IN THE PRESENCE OF WATER AND ALCOHOLS

D. Ramsden, J. A. Medley, 1960 .

Pharmacokinetic evaluation of poorly soluble compounds formulated as nano- or microcrystals after intraperitoneal injection to mice.

N. Hariparsad, D. Ramsden, D. Mcginnity, 2023, International journal of pharmaceutics.

Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Cocultured Human Hepatocyte System, HepatoPac

Mitchell E Taub, D. Tweedie, Yongmei Li, 2014, Drug Metabolism and Disposition.

Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective

K. Venkatakrishnan, N. Hariparsad, J. Bolleddula, 2021, Clinical pharmacology and therapeutics.

Identification and Characterization of a Selective Human Carbonyl Reductase 1 Substrate

D. Ramsden, M. Cerny, K. Frederick, 2018, Drug Metabolism And Disposition.

Evaluation of the drug–drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

D. Ramsden, S. Balani, M. Nishihara, 2021, Xenobiotica; the fate of foreign compounds in biological systems.

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes

D. Tweedie, Naitee Ting, R. Sane, 2016, Drug Metabolism and Disposition.

Novel insights in drug transporter sciences: the year 2021 in review

Charles J. Rotter, D. Ramsden, K. Tohyama, 2022, Drug metabolism reviews.

Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates

D. Tweedie, N. Hariparsad, M. Mohutsky, 2019, Drug Metabolism and Disposition.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

D. Tweedie, R. Walsky, M. Mohutsky, 2017, Drug Metabolism and Disposition.

Drug transporters in drug disposition – the year 2022 in review

Charles J. Rotter, D. Ramsden, K. Tohyama, 2023, Drug metabolism reviews.

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective

Hongbing Wang, M. Shebley, Liangfu Chen, 2016, Drug Metabolism and Disposition.

M. Manoharan, S. Chong, K. Charissé, 2022 .

Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations

D. Ramsden, V. Arya, Paresh P. Chothe, 2023, Drug Metabolism and Disposition.